Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats
Determine if maropitant decreases the minimum alveolar concentration (MAC) of sevoflurane during stimulation of the ovarian ligament in cats. Prospective study. Fifteen, female cats weighing 2.5 ± 0.6kg (mean ± SD). Anesthesia was induced and maintained with sevoflurane. The right ovary was accessed...
Gespeichert in:
| Veröffentlicht in: | Veterinary anaesthesia and analgesia 2013-07, Vol.40 (4), p.425-431 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 4 |
| container_start_page | 425 |
| container_title | Veterinary anaesthesia and analgesia |
| container_volume | 40 |
| creator | Niyom, Sirirat Boscan, Pedro Twedt, David C Monnet, Eric Eickhoff, Jens C |
| description | Determine if maropitant decreases the minimum alveolar concentration (MAC) of sevoflurane during stimulation of the ovarian ligament in cats.
Prospective study.
Fifteen, female cats weighing 2.5 ± 0.6kg (mean ± SD).
Anesthesia was induced and maintained with sevoflurane. The right ovary was accessed via laparoscopy. A suture around the ovary and ovarian ligament was exteriorized through the abdominal wall for stimulation. A stimulus–response curve was created to identify the optimal force for MAC comparisons. In 10 cats, MAC was determined with only sevoflurane (baseline) then after 1 and 5 mg kg−1 intravenous maropitant administration. The stimulation tension force used was 4.9 N. Repeated measures anova was used to compare the groups. MAC was defined as the average of the cross‐over concentrations and reported MAC is adjusted to sea‐level and depicted as mean ± SD.
The stimulus‐response curve was hyperbolic and plateaued at 4.3 ± 3 N. The optimal tension force chosen to compare MAC was 4.9 N. The baseline sevoflurane MAC was 2.96 ± 0.3%. Maropitant, 1 mg kg−1, decreased the MAC to 2.51 ± 0.3% (15%, p < 0.01). The higher maropitant dose of 5 mg kg−1 did not change MAC further when compared to the low dose (2.46 ± 0.4%, p = 0.33).
The ovarian ligament stimulation model is suitable to determine MAC during visceral stimulation in cats. Maropitant decreased the anesthetic requirements during visceral ovarian and ovarian ligament stimulation in cats. Maropitant (1 mg kg−1) decreases MAC by 15%; a higher dose had no additional effect. |
| doi_str_mv | 10.1111/vaa.12017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1367885604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1467298716302896</els_id><sourcerecordid>1367885604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4077-5c1f3855f73957c97e330eb6c76f732fc93ef063447dfbf92be689eb4d9424153</originalsourceid><addsrcrecordid>eNp1kU1u1TAURiMEoqUwYAPIQ5BIa8dJnAyfqr4WqQKK-BMTy3GuH6aJ_bCdQGcsgT2wM1bCLWnfCDyxZZ_v05VPlj1m9JDhOpqVOmQFZeJOts_KWuRF21Z3d-dG7GUPYvxCkWgrej_bK3hJ66qo97NfJ8aATsQbMqrgtzYpl54TRRxMwV9aZ93vHz8ZCaBhm3wg-Kw23tmIlHckfQYyIjVOI1HDDH5QgWjvNLgUVLKIYHWE2ZthCsoB6adg3YbEhJlhR1z3-FkFqxwZ7EaNmCfWEa1SfJjdM2qI8OhmP8jerU_eHp_l569OXxyvznNdUiHySjPDm6oygreV0K0Azil0tRY1XhVGtxwMrXlZit50pi06qJsWurJvy6JkFT_Ini692-C_ThCTHG3UMAw4tp-iZLwWTVPVtET02YLq4GMMYOQ2WPzAK8movHYi0Yn86wTZJze1UzdCvyNvJSBwtADf7ABX_2-S71er28p8SaAG-L5LqHApa8FFJT-8PJUXH9evP529uZBr5PnCA37fbCHIqC2gpN6i2CR7b_8x-B-k_7sR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367885604</pqid></control><display><type>article</type><title>Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>Niyom, Sirirat ; Boscan, Pedro ; Twedt, David C ; Monnet, Eric ; Eickhoff, Jens C</creator><creatorcontrib>Niyom, Sirirat ; Boscan, Pedro ; Twedt, David C ; Monnet, Eric ; Eickhoff, Jens C</creatorcontrib><description>Determine if maropitant decreases the minimum alveolar concentration (MAC) of sevoflurane during stimulation of the ovarian ligament in cats.
Prospective study.
Fifteen, female cats weighing 2.5 ± 0.6kg (mean ± SD).
Anesthesia was induced and maintained with sevoflurane. The right ovary was accessed via laparoscopy. A suture around the ovary and ovarian ligament was exteriorized through the abdominal wall for stimulation. A stimulus–response curve was created to identify the optimal force for MAC comparisons. In 10 cats, MAC was determined with only sevoflurane (baseline) then after 1 and 5 mg kg−1 intravenous maropitant administration. The stimulation tension force used was 4.9 N. Repeated measures anova was used to compare the groups. MAC was defined as the average of the cross‐over concentrations and reported MAC is adjusted to sea‐level and depicted as mean ± SD.
The stimulus‐response curve was hyperbolic and plateaued at 4.3 ± 3 N. The optimal tension force chosen to compare MAC was 4.9 N. The baseline sevoflurane MAC was 2.96 ± 0.3%. Maropitant, 1 mg kg−1, decreased the MAC to 2.51 ± 0.3% (15%, p < 0.01). The higher maropitant dose of 5 mg kg−1 did not change MAC further when compared to the low dose (2.46 ± 0.4%, p = 0.33).
The ovarian ligament stimulation model is suitable to determine MAC during visceral stimulation in cats. Maropitant decreased the anesthetic requirements during visceral ovarian and ovarian ligament stimulation in cats. Maropitant (1 mg kg−1) decreases MAC by 15%; a higher dose had no additional effect.</description><identifier>ISSN: 1467-2987</identifier><identifier>EISSN: 1467-2995</identifier><identifier>DOI: 10.1111/vaa.12017</identifier><identifier>PMID: 23406526</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Anesthetics, Inhalation - administration & dosage ; Anesthetics, Inhalation - pharmacology ; Animals ; Cats ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; maropitant ; Methyl Ethers - administration & dosage ; Methyl Ethers - pharmacology ; minimum alveolar concentration ; neurokinin-1 receptor ; Neurokinin-1 Receptor Antagonists - pharmacology ; Ovariectomy - veterinary ; Quinuclidines - administration & dosage ; Quinuclidines - pharmacology ; sevoflurane</subject><ispartof>Veterinary anaesthesia and analgesia, 2013-07, Vol.40 (4), p.425-431</ispartof><rights>2013 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia</rights><rights>2013 The Authors. Veterinary Anaesthesia and Analgesia © 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia</rights><rights>2013 The Authors. Veterinary Anaesthesia and Analgesia © 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4077-5c1f3855f73957c97e330eb6c76f732fc93ef063447dfbf92be689eb4d9424153</citedby><cites>FETCH-LOGICAL-c4077-5c1f3855f73957c97e330eb6c76f732fc93ef063447dfbf92be689eb4d9424153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvaa.12017$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvaa.12017$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23406526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niyom, Sirirat</creatorcontrib><creatorcontrib>Boscan, Pedro</creatorcontrib><creatorcontrib>Twedt, David C</creatorcontrib><creatorcontrib>Monnet, Eric</creatorcontrib><creatorcontrib>Eickhoff, Jens C</creatorcontrib><title>Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats</title><title>Veterinary anaesthesia and analgesia</title><addtitle>Vet Anaesth Analg</addtitle><description>Determine if maropitant decreases the minimum alveolar concentration (MAC) of sevoflurane during stimulation of the ovarian ligament in cats.
Prospective study.
Fifteen, female cats weighing 2.5 ± 0.6kg (mean ± SD).
Anesthesia was induced and maintained with sevoflurane. The right ovary was accessed via laparoscopy. A suture around the ovary and ovarian ligament was exteriorized through the abdominal wall for stimulation. A stimulus–response curve was created to identify the optimal force for MAC comparisons. In 10 cats, MAC was determined with only sevoflurane (baseline) then after 1 and 5 mg kg−1 intravenous maropitant administration. The stimulation tension force used was 4.9 N. Repeated measures anova was used to compare the groups. MAC was defined as the average of the cross‐over concentrations and reported MAC is adjusted to sea‐level and depicted as mean ± SD.
The stimulus‐response curve was hyperbolic and plateaued at 4.3 ± 3 N. The optimal tension force chosen to compare MAC was 4.9 N. The baseline sevoflurane MAC was 2.96 ± 0.3%. Maropitant, 1 mg kg−1, decreased the MAC to 2.51 ± 0.3% (15%, p < 0.01). The higher maropitant dose of 5 mg kg−1 did not change MAC further when compared to the low dose (2.46 ± 0.4%, p = 0.33).
The ovarian ligament stimulation model is suitable to determine MAC during visceral stimulation in cats. Maropitant decreased the anesthetic requirements during visceral ovarian and ovarian ligament stimulation in cats. Maropitant (1 mg kg−1) decreases MAC by 15%; a higher dose had no additional effect.</description><subject>Anesthetics, Inhalation - administration & dosage</subject><subject>Anesthetics, Inhalation - pharmacology</subject><subject>Animals</subject><subject>Cats</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>maropitant</subject><subject>Methyl Ethers - administration & dosage</subject><subject>Methyl Ethers - pharmacology</subject><subject>minimum alveolar concentration</subject><subject>neurokinin-1 receptor</subject><subject>Neurokinin-1 Receptor Antagonists - pharmacology</subject><subject>Ovariectomy - veterinary</subject><subject>Quinuclidines - administration & dosage</subject><subject>Quinuclidines - pharmacology</subject><subject>sevoflurane</subject><issn>1467-2987</issn><issn>1467-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1u1TAURiMEoqUwYAPIQ5BIa8dJnAyfqr4WqQKK-BMTy3GuH6aJ_bCdQGcsgT2wM1bCLWnfCDyxZZ_v05VPlj1m9JDhOpqVOmQFZeJOts_KWuRF21Z3d-dG7GUPYvxCkWgrej_bK3hJ66qo97NfJ8aATsQbMqrgtzYpl54TRRxMwV9aZ93vHz8ZCaBhm3wg-Kw23tmIlHckfQYyIjVOI1HDDH5QgWjvNLgUVLKIYHWE2ZthCsoB6adg3YbEhJlhR1z3-FkFqxwZ7EaNmCfWEa1SfJjdM2qI8OhmP8jerU_eHp_l569OXxyvznNdUiHySjPDm6oygreV0K0Azil0tRY1XhVGtxwMrXlZit50pi06qJsWurJvy6JkFT_Ini692-C_ThCTHG3UMAw4tp-iZLwWTVPVtET02YLq4GMMYOQ2WPzAK8movHYi0Yn86wTZJze1UzdCvyNvJSBwtADf7ABX_2-S71er28p8SaAG-L5LqHApa8FFJT-8PJUXH9evP529uZBr5PnCA37fbCHIqC2gpN6i2CR7b_8x-B-k_7sR</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Niyom, Sirirat</creator><creator>Boscan, Pedro</creator><creator>Twedt, David C</creator><creator>Monnet, Eric</creator><creator>Eickhoff, Jens C</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201307</creationdate><title>Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats</title><author>Niyom, Sirirat ; Boscan, Pedro ; Twedt, David C ; Monnet, Eric ; Eickhoff, Jens C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4077-5c1f3855f73957c97e330eb6c76f732fc93ef063447dfbf92be689eb4d9424153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anesthetics, Inhalation - administration & dosage</topic><topic>Anesthetics, Inhalation - pharmacology</topic><topic>Animals</topic><topic>Cats</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>maropitant</topic><topic>Methyl Ethers - administration & dosage</topic><topic>Methyl Ethers - pharmacology</topic><topic>minimum alveolar concentration</topic><topic>neurokinin-1 receptor</topic><topic>Neurokinin-1 Receptor Antagonists - pharmacology</topic><topic>Ovariectomy - veterinary</topic><topic>Quinuclidines - administration & dosage</topic><topic>Quinuclidines - pharmacology</topic><topic>sevoflurane</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niyom, Sirirat</creatorcontrib><creatorcontrib>Boscan, Pedro</creatorcontrib><creatorcontrib>Twedt, David C</creatorcontrib><creatorcontrib>Monnet, Eric</creatorcontrib><creatorcontrib>Eickhoff, Jens C</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary anaesthesia and analgesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niyom, Sirirat</au><au>Boscan, Pedro</au><au>Twedt, David C</au><au>Monnet, Eric</au><au>Eickhoff, Jens C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats</atitle><jtitle>Veterinary anaesthesia and analgesia</jtitle><addtitle>Vet Anaesth Analg</addtitle><date>2013-07</date><risdate>2013</risdate><volume>40</volume><issue>4</issue><spage>425</spage><epage>431</epage><pages>425-431</pages><issn>1467-2987</issn><eissn>1467-2995</eissn><abstract>Determine if maropitant decreases the minimum alveolar concentration (MAC) of sevoflurane during stimulation of the ovarian ligament in cats.
Prospective study.
Fifteen, female cats weighing 2.5 ± 0.6kg (mean ± SD).
Anesthesia was induced and maintained with sevoflurane. The right ovary was accessed via laparoscopy. A suture around the ovary and ovarian ligament was exteriorized through the abdominal wall for stimulation. A stimulus–response curve was created to identify the optimal force for MAC comparisons. In 10 cats, MAC was determined with only sevoflurane (baseline) then after 1 and 5 mg kg−1 intravenous maropitant administration. The stimulation tension force used was 4.9 N. Repeated measures anova was used to compare the groups. MAC was defined as the average of the cross‐over concentrations and reported MAC is adjusted to sea‐level and depicted as mean ± SD.
The stimulus‐response curve was hyperbolic and plateaued at 4.3 ± 3 N. The optimal tension force chosen to compare MAC was 4.9 N. The baseline sevoflurane MAC was 2.96 ± 0.3%. Maropitant, 1 mg kg−1, decreased the MAC to 2.51 ± 0.3% (15%, p < 0.01). The higher maropitant dose of 5 mg kg−1 did not change MAC further when compared to the low dose (2.46 ± 0.4%, p = 0.33).
The ovarian ligament stimulation model is suitable to determine MAC during visceral stimulation in cats. Maropitant decreased the anesthetic requirements during visceral ovarian and ovarian ligament stimulation in cats. Maropitant (1 mg kg−1) decreases MAC by 15%; a higher dose had no additional effect.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>23406526</pmid><doi>10.1111/vaa.12017</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1467-2987 |
| ispartof | Veterinary anaesthesia and analgesia, 2013-07, Vol.40 (4), p.425-431 |
| issn | 1467-2987 1467-2995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1367885604 |
| source | MEDLINE; Wiley Online Library All Journals; Alma/SFX Local Collection |
| subjects | Anesthetics, Inhalation - administration & dosage Anesthetics, Inhalation - pharmacology Animals Cats Dose-Response Relationship, Drug Drug Therapy, Combination Female maropitant Methyl Ethers - administration & dosage Methyl Ethers - pharmacology minimum alveolar concentration neurokinin-1 receptor Neurokinin-1 Receptor Antagonists - pharmacology Ovariectomy - veterinary Quinuclidines - administration & dosage Quinuclidines - pharmacology sevoflurane |
| title | Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A09%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20maropitant,%20a%20neurokinin%E2%80%901%20receptor%20antagonist,%20on%20the%20minimum%20alveolar%20concentration%20of%20sevoflurane%20during%20stimulation%20of%20the%20ovarian%20ligament%20in%20cats&rft.jtitle=Veterinary%20anaesthesia%20and%20analgesia&rft.au=Niyom,%20Sirirat&rft.date=2013-07&rft.volume=40&rft.issue=4&rft.spage=425&rft.epage=431&rft.pages=425-431&rft.issn=1467-2987&rft.eissn=1467-2995&rft_id=info:doi/10.1111/vaa.12017&rft_dat=%3Cproquest_cross%3E1367885604%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1367885604&rft_id=info:pmid/23406526&rft_els_id=S1467298716302896&rfr_iscdi=true |